Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) GlobeNewswire September 17, 2025 Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including measurements of skin disease, muscle disease, […]

Visit Philadelphia, TED Launch International Idea Search for Democracy-Focused TED Talks Anyone can apply by Nov. 30 to speak at TED Democracy Philadelphia: Founding Futures in June 2026. A touring Dear Democracy activation begins today. GlobeNewswire September 17, 2025 Philadelphia, Sept. 17, 2025 (GLOBE NEWSWIRE) — PHILADELPHIA, September 17, 2025 – Visit Philadelphia and TED

The Distillery Winter Village Returns November 13 Tickets On Sale Now for 2025 Season GlobeNewswire September 17, 2025 Toronto, ON, Sept. 17, 2025 (GLOBE NEWSWIRE) — Christmas may still be months away, but Toronto's original and world-famous Christmas Market is already counting down to opening night. The Distillery Winter Village returns November 13, 2025 –

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses GlobeNewswire September 17, 2025 Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621's oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis GlobeNewswire September 17, 2025 Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was generally well tolerated Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor,

Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025 GlobeNewswire September 17, 2025 FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the inaugural 2025 America's Greatest Companies list, published by Newsweek. The ranking honors

Microbix Client Labquality Introduces Novel EQA Scheme at ESCV Supporting Clinical Labs in Accurately Identifying HPV-associated Head and Neck Cancers GlobeNewswire September 17, 2025 MISSISSAUGA, Ontario and HELSINKI, Sept. 17, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix(R)), a life sciences innovator, manufacturer, and exporter, and Labquality Oy (Labquality), announce a novel

Baker Hughes Secures Multi-Year Contract with Petrobras for Offshore Stimulation Vessels GlobeNewswire September 17, 2025 Contract extension for two stimulation vessels supports offshore operations in Brazil's post and pre-salt fields Award reinforces Baker Hughes' Mature Assets Solutions strategy to deliver greater customer value for enhanced brownfield recovery HOUSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE)

Snow melts earlier in burned forests, new Science Advances study finds Study led by Colorado School of Mines researchers raises concerns about water supply risks GlobeNewswire September 17, 2025 GOLDEN, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) — Wildfires are causing earlier snowmelt across the western U.S., and this effect would only be exacerbated by projected

AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning GlobeNewswire September 17, 2025 PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) — AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced an expansion